Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG) is a pioneering American corporation headquartered in Sunnyvale, California. The company specializes in the development, manufacturing, and marketing of advanced robotic products that enhance clinical outcomes through minimally invasive surgical techniques. The cornerstone of Intuitive Surgical's innovation is the da Vinci Surgical System, a state-of-the-art robotic platform designed to facilitate complex surgeries with precision and control.
Intuitive Surgical's mission is to transform the surgical experience by providing surgeons with innovative tools that enable better patient outcomes. The da Vinci Surgical System offers a highly magnified, three-dimensional view and robotic assistance, helping surgeons perform precise dissections and reconstructions deep within the body. The system includes several models, including the multiport da Vinci X and Xi and the single-port da Vinci SP, giving hospitals and surgeons versatile options tailored to their needs.
The company has successfully installed over 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 of these installations in the United States alone. The growing presence of these systems in emerging markets underscores the global demand for cutting-edge surgical technology.
In recent news, Intuitive Surgical announced the FDA clearance of its latest generation system, the da Vinci 5, which builds on over a decade of research and offers more than 150 enhancements. This new system aims to improve patient outcomes further, enhance the surgical experience, and reduce overall healthcare costs. Initial deployment of the da Vinci 5 will be limited to select U.S. hospitals with mature robotic surgery programs, before a broader commercial launch.
Intuitive's financial performance remains robust, as highlighted in its recent quarterly reports. The company continues to experience growth in revenue and market penetration, driven by the increasing adoption of robotic-assisted surgery. Its strategic partnerships and collaborations further solidify its market leadership and commitment to innovation.
Intuitive Surgical also emphasizes continuous learning and support for surgical teams, offering comprehensive training programs and educational resources to ensure optimal use of its technologies. The company's dedication to advancing healthcare is reflected in its robust research and development initiatives, aimed at expanding the capabilities and applications of robotic-assisted surgery.
For more detailed financial and operational updates, please visit Intuitive Surgical's official website at www.intuitive.com.
Intuitive has been recognized as the largest provider of robotic-assisted surgical technology training accredited by the Royal College of Surgeons of England. This global accreditation highlights Intuitive's commitment to excellence in surgery-related education, having trained over 60,000 surgeons worldwide on their da Vinci Surgical Systems. The recognition confirms the quality and safety of their educational programs, ensuring surgeons confidently adopt new technologies. Dr. Gillian Duncan emphasized the importance of high training standards in maximizing robotic surgery benefits.
Intuitive (Nasdaq: ISRG) reported Q3 2022 revenue of $1.56 billion, marking an 11% increase from $1.40 billion in Q3 2021. Worldwide da Vinci procedures grew by approximately 20%, rebounding from COVID-19 disruptions. Despite placing 305 da Vinci Surgical Systems, down 9% from 336 systems in Q3 2021, the company’s installed base rose to 7,364 systems, a 13% increase. GAAP net income fell to $324 million ($0.90/share) from $381 million ($1.04/share) in the prior year.
The company repurchased $1 billion of common stock and ended the quarter with $7.39 billion in cash and investments.
Intuitive has received clearance from Japan's Ministry of Health for its da Vinci SP surgical system, making it the first single-port robotic surgical system approved in the country. This system will facilitate general, thoracic (non-cardiac), urologic, gynecological, and head and neck surgeries. With this approval, Intuitive aims to enhance minimally invasive surgical options for Japanese surgeons. The company anticipates launching the SP system soon, complementing its existing multi-port systems and expanding access to robotic-assisted procedures.
Optellum, a medtech company based in Oxford, has raised $14 million in a Series A funding round led by Mercia, with participation from Intuitive Ventures and Black Opal Ventures. This funding will be used to scale operations and commercial launches in the UK and USA, accelerate R&D, and enhance its AI platform for lung cancer diagnosis. Optellum is recognized for its groundbreaking approach to early lung cancer detection, aiming to improve survival rates significantly as lung cancer remains a leading cause of cancer deaths worldwide.
Luna Innovations Incorporated (NASDAQ: LUNA) has announced a new $14.2 million contract with Intuitive Surgical (NASDAQ: ISRG) to supply critical photonic subsystems for advanced robotic surgical systems. This contract underscores Luna's commitment to long-term, recurring sales and highlights the growing role of its technologies in surgical robotics. CEO Scott Graeff emphasized the company's growth potential in this expanding market and the significance of their products, such as the PHOENIX™ tunable laser, in enhancing surgical outcomes.
Intuitive (Nasdaq: ISRG) reported Q2 2022 financial results, highlighting a 4% increase in revenue to $1.52 billion, driven by a 14% growth in da Vinci procedures despite ongoing COVID-19 disruptions. The company placed 279 surgical systems, a 15% decline year-over-year. GAAP net income decreased to $308 million or $0.85 per diluted share, down from $517 million or $1.42 the previous year. The company repurchased $500 million in common stock and increased stock repurchase authorization to $3.5 billion.
Intuitive (Nasdaq: ISRG) has received FDA clearance for the integration of mobile cone-beam CT imaging technology with its Ion Endoluminal System, enhancing robotic bronchoscopy procedures. This collaboration with Siemens Healthineers allows for improved 2D and 3D imaging, increasing diagnostic yield to approximately 80%. Initial studies suggest a 10% improvement in biopsy accuracy when using the Cios Spin with Ion. This advancement aims to enhance early lung cancer diagnosis, which significantly affects survival rates.
Intuitive (Nasdaq: ISRG) reported Q1 2022 results, revealing revenue of $1.49 billion, up 15% from $1.29 billion in Q1 2021. The increase was driven by a 19% rise in da Vinci procedures. The company placed 311 da Vinci Surgical Systems, marking a 4% increase. However, GAAP net income fell to $366 million ($1.00 per share), down from $426 million ($1.17 per share) in the prior year. COVID-19 continued to impact procedure volumes, but customer demand remained strong. The company ended the quarter with $8.40 billion in cash and investments.
Intuitive (Nasdaq: ISRG) reported Q4 2021 revenue of $1.55 billion, a 17% increase from Q4 2020, propelled by a 19% rise in da Vinci procedures. The company shipped 385 da Vinci Surgical Systems, up 18% year-over-year. GAAP net income reached $381 million ($1.04 per diluted share), while non-GAAP net income was $477 million ($1.30 per diluted share). However, the resurgence of COVID-19 impacted procedure volumes. The firm ended the quarter with $8.6 billion in cash and investments.
Intuitive (Nasdaq: ISRG) reported preliminary financial results for Q4 and full year 2021. Q4 revenue reached approximately $1.55 billion, up 17% from $1.33 billion in Q4 2020. Full-year revenue was about $5.71 billion, a 31% increase from 2020. The company shipped 385 da Vinci Surgical Systems in Q4 2021, marking an 18% increase year-over-year. Additionally, da Vinci procedures grew approximately 19% in Q4 2021 compared to 2020. The company also received FDA clearance for a new 8 mm surgical stapler.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
What is Intuitive Surgical Inc.?
What is the da Vinci Surgical System?
How many da Vinci systems are installed globally?
What recent achievements has Intuitive Surgical announced?
Are there different models of the da Vinci system?
What is the company's focus regarding patient care?
Where is Intuitive Surgical headquartered?
Does Intuitive Surgical offer training for its systems?
How can I get more information about Intuitive Surgical's financial performance?
What is the significance of the da Vinci 5 system?
